Avalo Therapeutics, Inc. (AVTX)
14.21
-1.76
(-11.02%)
USD |
NASDAQ |
Feb 20, 16:00
14.17
-0.04
(-0.28%)
After-Hours: 20:00
Avalo Therapeutics EPS Diluted (Quarterly) : -2.187 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AbbVie, Inc. | 1.024 |
| ACADIA Pharmaceuticals, Inc. | 0.4206 |
| Alnylam Pharmaceuticals, Inc. | 1.368 |
| Savara, Inc. | -0.1366 |
| BioMarin Pharmaceutical, Inc. | -0.1601 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -30.62M |
| Total Expenses (Quarterly) | 30.62M |
| Enterprise Value | 153.91M |
| Earnings Yield | -61.43% |
| Normalized Earnings Yield | -45.17 |